NGOC Clinical Trials List - Printable Version

Head and Neck (C00-C14)

1. Locally Advanced
2. 1st Line Recurrent / Metastatic
3. Previously Treated

Esophagus/Gastric (C15-C16)

1. Stage II- IV, Neo-adjuvant
2. First Line, Recurrent or Metastatic
    a. **AZ D702AC00001 (Artemide-Gastric01) A Phase 3 Study of Rilvegostomig in Combination with Fluoropyrimidine** — **Open 8/12/25**
        i. Arm A: Rilvegostomig + T-Dxd + Investigator's Choice: 5-FU or Capecitabine
        ii. Arm B: Pembro + trastuzumab + Investigator's choice: Cisplatin+ 5FU or CAPOX+capecitabine
        iii. Arm C: Rilvegostomic (750mg IV Q3w) + Trastuzumab + Investigator's Choice: Cisplatin+5FU OR CAPOX+Capecitabine
3. Previously Treated
    a. **AZ D9802C00001 (Clarity) AZD0901 compared with Investigator's choice of therapy in participants** — **Open 8/13/24**
        i. Arm 1: AZD0901 2.2 mg/kg IV Q3W
        ii. CLOSED - Arm 2: AZD0901 1.8 mg/kg IV Q3W
        iii. Arm 3: Investigator's choice of therapy (ramucirumab, paclitaxel, docetaxel, irinotecan, TAS-102, and apatinib)

Biliary (K83.9)

1. First Line Therapy

Pancreas (C25)

1. Adjuvant / NeoAdjuvant
2. 1st Line, Metastatic
    a. **BMS CA240-0030 (MountainTAP) Study of BMS-986504 in Combination with Nab-p/Gem versus Placebo in Co** — **Pending 8/26/25**
        i. Phase 2 Dose Selection Arm A: BMS-986504 400mg + Nab-Pac + Gem
        ii. Phase 2 Dose Selection Arm B: BMS-986504 600mg + Nab-Pac + Gem
        iii. Phase 2 Dose Selection Arm C: BMS-986504 400mg Placebo + Nab-Pac + Gem
        iv. Phase 2 Dose Selection Arm D: BMS-986504 600mg Placebo + Nab-Pac + Gem
        v. NOT YET OPEN Phase 3 Arm E: BMS-986504 Optimal Dose + Nab-Pac + Gem
        vi. NOT YET OPEN Phase 3 Arm F: BMS-986504 Optimal Dose Placebo + Nab-Pac + Gem
3. Previously Treated

Colon & Rectum (C18-C20)

1. Stage III, Resected Colon, Adjuvant
2. Stage IV, Metastatic, 1st Line, Colon or Rectum
3. Metastatic, 3rd Line, Colon
    a. **AbbVie M24-064 Phase 3 comparing Abbv-400 Monotherapy vs Lonsurf+Bevacizumab in subj** — **Pending 3/10/25**
        i. CLOSED: Stage 1 Arm A: AbbV-400 2.0mg/kg IV Q3W
        ii. CLOSED: Stage 1 Arm B: AbbV-400 2.4mg/kg IV Q3W
        iii. NOT OPEN Stage 2 Arm A: AbbV-400 Optimal Dose IV Q3W
        iv. NOT OPEN Stage 2 Arm B: LONSURF 35mg/m2 PO BID + Bevacizumab 5mg/kg IV q2w
4. Metastatic 2nd or 3rd Line, KRAS Mutated
5. Metastatic 2nd or 3rd Line, KRAS Wild Type
6. Refractory

Lung, Squamous Cell (C34)
1. Stage IV, Metastatic
2. Second Line

Lung, Non-Small Cell (C34)
1. Stage IB, II, IIIA; Adjuvant
2. Stage 1B, II, Resectable IIIA
3. Stage II-III Resected
4. Stage IIIA-IIIB, Locally Advanced, Unresectable
5. Stage IIB-IIIB Resected and Chemotherapy-Naive Stage IV
6. First Line- Metastatic
7. Stage IV, Metastatic
8. 2nd or 3rd Line
9. Metastatic, Previously Treated
    a. **MK 2870-004 Phase 3 Study of MK-2870 vs Chemo Previously Treated Advanced or Metas** **Open 1/9/24**
        i. Arm A: MK-2870 4mg/KG IV Days 1,15, & 29 every 6 week cycle
        ii. Arm B: Investigator's choice of Docetaxel 75mg/m2 IV or Pemetrexed 500mg/m2 IV on Days 1 and 22 of 6 week cycle

Mesothelioma (C45)
1.

Lung, Small Cell (C34)
1. Extensive Stage, Small Cell Lung Ca
    a. **BMS CA245-0001 A Randomized, Double-Blind, Multicenter Phase 3 Trial** **Open 1/24/25**
        i. Arm A:BMS-986489 420mg/nivolumab 360 mg IV+carboplatin+etoposide
        ii. Arm B: atezolizumab 1200mg IV+carboplatin+etoposide
2. Previously Treated

Breast, Adjuvant (C50)
1. NeoAdjuvant, Stage I, II, III
2. Adjuvant
    a. **GS-US-595-6184 (ASCENT-05) A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govite** **Open 1/31/23**
        i. Arm A: Sacituzumab Govitecan 10mg/kg IV Days 1 and 8 + Pembrolizumab 200mg IV Day 1 Q3W X 8 cycles
        ii. Arm B: Treatment of Physician's Choice: Pembrolizumab 200mg IV Day 1 Q3 weeks X 8 cycles OR Pembrolizumab 200 mg IV Day 1 and Capecitabine 1000 mg/m2 PO BID D1-D14 Q3 Weeks X 8 cycles

Breast, Her-2 Positive (C50)
1. NeoAdjuvant HER-2 Positive
2. Adjuvant, HER-2 Positive
3. Metastatic, HER-2 Positive, 1st Line
4. Metastatic, Previously Treated, Her-2 Positive

Breast, Advanced (C50)
1. Stage IV, Metastatic, 1st Line
    a. **RGN WO45654 (INAVO123) A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED** **Open 5/23/25**
        i. Arm A: Inavolisib 9mg tablet PO QD days 1-28 of 28 day cycle + palbociclib 125mg PO QD D1-21 of 28 + letrozole 2.5mg PO QD
        ii. Arm B: Placebo tablet PO QD days 1-28 of 28 day cycle + palbociclib 125mg PO QD D1-21 of 28 + letrozole 2.5mg PO QD
2. Stage IV, Metastatic, ER -
3. Stage IV, Metastatic, Previously Treated
4. Stage IV, Metastatic, Triple Negative Breast Cancer

Breast, ER Positive (C50)
1. Adjuvant
    a. **AZ D8535C00001 (Cambria 2) Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER** **Open 3/5/24**
        i. Arm A: Standard ET (AI or tamoxifen)+/-abemaciclib (+/-LHRH agonist*)
        ii. Arm B: Camizestrant 75 mg/daily +/- abemaciclib (+/- LHRH agonist*)
2. Metastatic, First Line

3. Metastatic, Prior Hormonal Therapy

Melanoma (C43)
1. Adjuvant
2. Locally advanced or Metastatic
3. Previously Treated

Ovarian (C56)
1. Previously Treated

Bladder (C67)
1.
2. Urothelial

Renal (C64)
1. Adjuvant, Phase III
2. First Line Treatment, Advanced or Metastatic
3. Advanced, Metastatic
4. Previously Treated

Prostate (C61)
1. Hormone Refractory, 1st Line
2. 1st line Metastatic
3. Metastatic, 2nd Line Prostate
4. Hormone Refractory; Bone Predominant 3rd Line or Greater

Sarcoma (C46-C49)
1. Sarcoma, Previously Treated

Adrenal (C74)
1. Previously Treated

Lymphoma (C82-C88)
1. Indolent, previously treated
2. Follicular, First Line
3. Indolent, Relapsed
4. Relapsed or Refractory; DLBCL, FL
5. Large Cell Lymphoma, Relapsed/Refractory
6. Relapsed and Refractory Folllicular Lymphoma
    a. **BMS CA073-1003 A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Ef** — **Open 8/13/25**
        i. Arm A: R-Golca 0.4mg D1-14/48 days+Rituximab x5cycles followed by golcadomide monotherapy for up to 12 cycles of toral therapy
        ii. Arm B: R-Len 20mg, Days 1-21, cycles 1-12,rituximab 375mg/m2, Days 1,8,15,and 22 in cycle 1; Day 1 in cycles 2-5 — *Accrual Goal* = 3
        iii. Arm B: R-Len 20mg, Days 1-21, cycles 1-12,rituximab 375mg/m2, Days 1,8,15,and 22 in cycle 1; Day 1 in cycles 2-5
        iv. Arm C: R-CHOP 6 cycles
7. Relapsed and Refractory Follicular or Marginal Zone Lymphoma
8. Diffuse Large Cell, First Line
9. Mantle Cell Lymphoma

CNS (C71)
1. Glioblastoma Multiforme

Leukemia (C91-C92)
1. CLL, First Line
    a. **BGB-11417-204 A Phase 2 Study to Investigate Sonrotoclax Combined With Zanubrutinib** — **Open 12/16/24**
        i. Arm A: Zanubrutinib 320mg PO QD for 3 cycles followed by Sonrotoclax (BGB-11417)Ramp up to Target 320mg QD PO + Zanbrutinib (BGB-3111) 320mg PO for 12 Cycles
        ii. Arm B: Zanubrutinib (BGB-3111) orally at 320 mg daily dose 28d Cycle Until Intolerance or PD
2. CLL, Relapsed or Refractory
3. CML

Myeloma (C90)
1. 1st Line
2. Relapsed / Refractory 1-3 Lines
3. Relapsed / Refractory > or equal to 2 Lines

MDS (D46)
1. 1st Line
2. Observational Registry

Unknown Primary (199)
1. 1st Line

Other
1. Tissue Studies
2. Observational Studies

Multiple Sites
1. Phase I
2. EMD MS100070-0176 (EMR100070-001 Rollover)
3. Novartis Signature Series
4. Solid Tumors, Refractory
5. Solid Tumors, Advanced or Metastatic

Supportive Care
1. Bone Mets
2. Anemia
3. Thrombocytopenia

this list was last updated on: 8/27/25